Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053)
SRPT press release – golodirsen NDA acceptance 02 14 19
SRPT press release – golodirsen NDA acceptance 02 14 19
We are excited about the UT Southwestern Wellstone Symposium on March 30! Don’t forget to RSVP by March 1. We’ll see you there! [download id=”13142″ template=”UT Southwestern Wellstone Symposium “]
Thursday February 28th at 4pm Dr. Eric Olson is giving a talk at the President’s Lecture at UT Southwestern (South Campus Gooch Auditorium) and will be highlighting the DMD project. Steve […]
We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by […]
We’re pleased to share this letter and news from our partner Santhera about their plans for 2019! For more than 10 years, Santhera has been working on treatments for DMD, […]
Highlights from day three at the World Muscle Society meeting in Mendoza, Argentina, provided by CureDuchnne’s scientist, Dr. Mike Kelly. Mallinckrodt Pharmaceuticals Mallinckrodt provided an update on their Phase 2 […]
Highlights from day two at the World Muscle Society meeting in Mendoza, Argentina, provided by CureDuchnne’s scientist, Dr. Mike Kelly. Sarepta’s Gene Therapy Program: Sarepta provided a much-anticipated update on […]
Highlights from the first day at the World Muscle Society meeting in Mendoza, Argentina, provided by CureDuchnne’s scientist, Dr. Mike Kelly. Carrier-mothers: It’s recognized that Duchenne and Becker muscular dystrophy […]
Dear Friends, Today, our partner Dr. Eric Olson and his team at Exonics, a company CureDuchenne helped form, published data in the online journal, Science that shows an increase in […]